Can an arthritis drug shield the lungs after a brain bleed?
NCT ID NCT06548802
First seen Oct 20, 2026 · Last updated Oct 21, 2026 · Updated 1 time
Summary
Some people who have a brain bleed develop serious lung injury, which can lead to breathing failure. Researchers are testing baricitinib, a drug that calms inflammation and is used in severe COVID-19, to see if it can reduce this lung damage. The trial enrolls adults with a recent non-traumatic brain bleed who develop breathing problems within a week of hospital admission. Participants take baricitinib daily for 14 days, and researchers track how quickly they recover their breathing and how their brain injury changes over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- baricitinib, an anti-inflammatory drug taken as a daily tablet
- What this could lead to
- If it works, baricitinib could become a way to calm the lung inflammation that follows a brain bleed and help patients breathe on their own sooner.
- What could go wrong
- This is an early-stage trial with about 100 patients, so results may not hold in larger groups. Baricitinib dampens the immune system, which may raise the risk of infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female patients ≥ 18 years old; 2. The diagnosis was non-traumatic intracerebral hemorrhage, subarachnoid hemorrhage (including supratentorial deep hemorrhage, lobal hemorrhage, cerebellar hemorrhage, brainstem hemorrhage, intracerebral hemorrhage, intracerebral parenchymal hemorrhage into ventricle, subarachnoid hemorrhage), which was confirmed by CT scan. 3. Onset of ARDS within 48 hours to 7 days after admission (as defined by Berlin) : ① Patients with moderate to severe ARDS symptoms or progressive dyspnea within 7 days (100mmHg \< PaO2/FiO2≤200, PEEP≥5cmH2O); ② Hypoxemia: SpO2/FiO2≤315mmHg and SpO2≤97%, and could not be explained by acute heart failure and fluid overload; ③ Need intubation or mechanical ventilation; ④ Imaging findings (chest X-ray/chest CT) : infiltration of both lungs, cannot be completely explained by pleural effusion, lobar/whole lung atelectasis and nodule; 4. There was no uncured pneumonia, interstitial lung disease, or chronic respiratory failure before the onset of the disease. 5. Able and willing to sign written informed consent and comply with the requirements of the research protocol. Exclusion Criteria: 1. Patients diagnosed with severe intracerebral hemorrhage requiring surgical intervention with decompressive craniotomy or critically ill, near death; 2. Diagnosis of aneurysm, brain tumor, arteriovenous malformation requires surgery; 3. Recently received live or attenuated vaccine; other JAK inhibitors or other organisms are being used, or enrolled in other clinical trials; 4. Combine the following cases that are not eligible to participate in this study: ① Severe hepatic insufficiency (ALT/AST \> 5xULN); ② Moderate to severe renal insufficiency (eGFR \< 60ml/min/1.73m2); ③ Undergoing hemodialysis or hemofiltration; ④ Neutrophils or lymphocytes decreased (Absolute neutrophil count \< 1000/ul, absolute lymphocyte count \< 200/ul); ⑤ During pregnancy or childbirth; 5. Venous thromboembolism or risk of thrombosis; 6. Life expectancy after enrollment ≤24h.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute respiratory distress syndrome are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300052, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Single donor banked bone marrow mesenchymal stromal cells for the treatment of COVID-19 induced ARDS: a Non-Blinded randomized, controlled study
- Force-Feedback VR put to the test for weak arms after brain bleed
- Can scans and blood tests forecast who recovers after a brain bleed?
- Stem cells from umbilical cords tested as new therapy for brain bleeds
- Can gentler breathing machines save ARDS patients on ECMO?
- Can stem cells rebuild the brain after a bleed?